// App-Quantinova.ai

P6-03-05 : Dual HER2 blockade of an activating driver HER3 mutation: A proof of principle study in a metastatic breast cancer patient

Researchers

Presenter

  • Bidard F-C

Principal Investigators

  • Tulukcuoglu E

  • Pierga J-Y

  • Reis-Filho JPiscuoglio SDescroix S

  • Mignot L

  • Viovy J-L

  • Cottu P

  • Sigal B

  • Vincent-Salomon A

  • Weigelt B

Medical Centers

  • Institut Curie, Paris Cedex, France

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • France

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Solid malignancies

Biomarkers

  • Circulating tumor cells

  • Epidermal growth factor receptor

  • Erb-B2 Receptor Tyrosine Kinase 3

  • Circulating DNA

Drug/Treatment

  • Trastuzumab

  • Lapatinib

  • taxane

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved